Evidence map›Paper›PMID 41006203›Full record

ArticleNature communications2025

Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphoma.

Ajay Subramanian, Shengqin Su, Jamie Flerlage, Stefan Alig, Sheren Younes, Lianna J Marks, Chelsea Pinnix, Francisco Vega, Raphael Steiner, Priya Kumar and 24 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Ajay Subramanian *Department of Radiation Oncology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-7892-886X
Shengqin Su *Department of Radiation Oncology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-6946-8256
Jamie FlerlageDepartment of Pediatrics, University of Rochester, Rochester, NY, USA.ORCID http://orcid.org/0000-0002-4182-9355
Stefan AligDepartment of Medicine, Division of Oncology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-6825-702X
Sheren YounesDepartment of Pathology, Stanford University, Stanford, CA, USA.
Lianna J MarksDepartment of Pediatrics, Division of Pediatric Hematology/Oncology, Stanford University, Stanford, CA, USA.
Chelsea PinnixDepartment of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Francisco VegaDepartment of Hematopathology, MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-5956-452X
Raphael SteinerDepartment of Lymphoma & Myeloma, MD Anderson Cancer Center, Houston, TX, USA.
Priya KumarDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0001-8945-6917
Heidi MocikovaDepartment of Hematology, Fakultni nemocnice Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czechia.
Alice Sykorova4th Department of Internal Medicine - Hematology, University Hospital and Faculty of Medicine, Hradec Kralove, Czechia.
Vit ProchazkaDepartment of Hemato-oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czechia.ORCID http://orcid.org/0000-0002-9861-3117
Cristiane MilitoDepartment of Pathology at the Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Pamela AllenDepartment of Hematology & Oncology Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Darina PaulinoDepartment of Hematology & Oncology Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Alan RamsayUniversity College London Hospitals NHS Foundation Trust, London, UK.
Timothy FlerlageDepartment of Infectious Diseases, University of Rochester, Rochester, NY, USA.
Monica PaleseDepartment of Pediatrics, University of Rochester, Rochester, NY, USA.ORCID http://orcid.org/0000-0002-2624-0868
Robert WestDepartment of Pathology, Stanford University, Stanford, CA, USA.
ChunFang ZhuDepartment of Pathology, Stanford University, Stanford, CA, USA.
Troy NoordenbosDepartment of Medicine, Division of Oncology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-0583-4584
Joseph Schroers-MartinDepartment of Medicine, Division of Oncology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-4128-2537
Shuchun ZhaoDepartment of Pathology, Stanford University, Stanford, CA, USA.
Natalie J ParkDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.
Anusha KalbasiDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-8692-1457
Everett J ModingDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-7913-5351
Aaron M NewmanDepartment of Biomedical Data Science, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-1857-8172
Ranjana H AdvaniDepartment of Medicine, Division of Oncology, Stanford University, Stanford, CA, USA.
Richard T HoppeDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-0125-0194
Maximilian DiehnDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-2032-0581
Yasodha NatkunamDepartment of Pathology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-9816-1018
Ash A AlizadehDepartment of Medicine, Division of Oncology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-5153-5625
Michael Sargent BinkleyDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA. msb996@stanford.edu.ORCID http://orcid.org/0000-0002-2640-5255

Funding

Investigating personalized approaches to de-intensify therapy for nodular lymphocyte-predominant Hodgkin lymphomaK08CA266824 · NCI · STANFORD UNIVERSITY · PI Michael S Binkley · 2024 to 2026
$854k
NCI NIH HHS K08 CA266824NCI NIH HHS L30 CA274784U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) K08CA266824
6 · The paper itself

Abstract

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare cancer, and few studies have comprehensively investigated the immune microenvironment and rare lymphocyte-predominant (LP) cells. Here we develop a NLPHL specific lymphocyte-predominant ecotype (LPE) model to identify 34 distinct cell states across 14 cell types that co-occur within 3 LPEs for 171 cases. LPE1 and LPE2 were characterized by immunosuppressive microenvironments with high expression of B2M on LP cells, CD8 T-cell exhaustion, immune checkpoint genes expressed by follicular T-cells, and an improved freedom from progression compared to LPE3 in training (n = 109, with 65% LPE1/2) and validation cohorts (n = 62, with 61% LPE1/2). We validate the co-occurrence and co-localization of cell states using spatial transcriptomics. Protein expression of HLA-I and HLA-II on LP cells and SSTR2 on dendritic cells was predictive of LPE1 (C-statistic=0.69), LPE2 (C-statistic=0.79), and LPE3 (C-statistic=0.60). This study establishes a clinically relevant biologic categorization for NLPHL.

Indexed as

Hodgkin DiseaseLymphocytesTumor MicroenvironmentAdultCD8-Positive T-LymphocytesDendritic CellsFemaleHumansMaleMiddle AgedTranscriptome

Identifiers

PMID41006203
PMCPMC12475200

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.